Under construction – not a live service
Sign in

2023-506210-40-00CompletedPhase 3

Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction

A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)

Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Apr 2025

Next steps

Brief summary (registry, in English)

To monitor safety and tolerability of vericiguat (MK-1242).

Status (registry)
Completed
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
99 (actual)
First submitted
16 Nov 2023
Start date
28 Jun 2024
Lead sponsor
Merck Sharp & Dohme LLC
EU CT number
2023-506210-40-00

What you commit to

  • Study type: Interventional · Phase 3
  • Participants enrolled: 99
  • 29 sites in 13 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has concurrent or anticipated concomitant use of phosphodiesterase type 5 inhibitors during the study
  • Has concurrent or anticipated use of an soluble guanylate cyclase (sGC) stimulator

Other illness

  • Has undergone heart transplantation or has an implanted ventricular assist device
  • Has severe chronic kidney disease or requires chronic dialysis
  • Has hepatic disorder or Child Pugh Class C

Age

  • Is hypotensive for age at Visit 1

Who the study is looking for

  • Has received at least 1 dose of study intervention (vericiguat or placebo) and completed the Week 52 visit and safety follow-up period for the VALOR base study. This includes participants who prematurely discontinued study intervention unless premature discontinuation of study intervention was due to a drug related adverse event (AE) or to noncompliance with study intervention
  • Is able to receive medication via the oral or gastric route

Age in the registry: - to 64 years · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (29)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Universitair Ziekenhuis GentGentBelgiumCompleted
UZ LeuvenLeuvenBelgiumCompleted
Centre Hospitalier Regional de la CitadelleLiègeBelgiumCompleted
Charite Universitaetsmedizin Berlin KöRBerlinGermanyCompleted
Universitaetsklinikum Erlangen AöRErlangenGermanyCompleted
Medical Center- University of FreiburgFreiburg im BreisgauGermanyCompleted
Medizinische Hochschule HannoverHanoverGermanyCompleted
Universitaetsklinikum Heidelberg AöRHeidelbergGermanyCompleted
RigshospitaletCopenhagen OeDenmarkCompleted
Sant Joan De Deu Barcelona HospitalEsplugues De LlobregatSpainCompleted
Hospital General Universitario Gregorio MarañónMadridSpainCompleted
Tampere University HospitalTampereFinlandCompleted
Centre Hospitalier Universitaire De LilleLille CedexFranceCompleted
Assistance Publique Hôpitaux de MarseilleMarseilleFranceCompleted
Centre Hospitalier Universitaire de NantesNantesFranceCompleted
Hopital Necker Enfants MaladesParisFranceCompleted
Robert Debre University HospitalParisFranceCompleted
Centre Hospitalier Universitaire de BordeauxPessacFranceCompleted
Gottsegen National Cardiovascular CenterBudapestHungaryCompleted
Children's Health IrelandDublinIrelandCompleted
Azienda Ospedaliera Universitaria Meyer IRCCSFlorenceItalyCompleted
Azienda Ospedale Universita PadovaPadovaItalyCompleted
Universitair Medisch Centrum GroningenGroningenNetherlandsCompleted
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCompleted
Uniwersyteckie Centrum KliniczneGdanskPolandCompleted
Centro Hospitalar De Lisboa Ocidental E.P.E.CarnaxidePortugalCompleted
Centro Hospitalar Universitario De Lisboa Norte E.P.E.LisbonPortugalCompleted
Sao Joao University Hospital CenterPortoPortugalCompleted
Region Skane Skanes UniversitetssjukhusLundSwedenCompleted

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.